JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

JNJ

229.55

+1.09%↑

UNH

369.43

+0.01%↑

TMO

477.23

+2.72%↑

ISRG

455.68

+0.57%↑

ABT

90.54

-1.43%↓

Search

Smith & Nephew PLC ADR

Geschlossen

30.89 1.68

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

30.35

Max

30.97

Schlüsselkennzahlen

By Trading Economics

Einkommen

35M

331M

Verkäufe

203M

3.2B

KGV

Branchendurchschnitt

22.441

67.147

Dividendenrendite

2.44

Gewinnspanne

10.368

Angestellte

16,988

EBITDA

133M

856M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+2.96% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.44%

2.36%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.5B

14B

Vorheriger Eröffnungskurs

29.21

Vorheriger Schlusskurs

30.89

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Smith & Nephew PLC ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

29. Apr. 2026, 23:53 UTC

Ergebnisse

Naver Posts Weaker First-Quarter Earnings

29. Apr. 2026, 23:41 UTC

Heiße Aktien

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29. Apr. 2026, 23:55 UTC

Ergebnisse

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29. Apr. 2026, 23:54 UTC

Ergebnisse

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29. Apr. 2026, 23:52 UTC

Ergebnisse

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29. Apr. 2026, 23:51 UTC

Ergebnisse

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29. Apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29. Apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29. Apr. 2026, 23:24 UTC

Ergebnisse

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan 1Q Net CNY1.70B, Down 14%

29. Apr. 2026, 23:22 UTC

Ergebnisse

China Longyuan: Power Generation Down 2.9% as of End-March

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29. Apr. 2026, 23:20 UTC

Ergebnisse

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29. Apr. 2026, 23:19 UTC

Ergebnisse

China Vanke 1Q Loss Narrows>000002.SZ

29. Apr. 2026, 23:18 UTC

Ergebnisse

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29. Apr. 2026, 23:17 UTC

Ergebnisse

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29. Apr. 2026, 23:15 UTC

Ergebnisse

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29. Apr. 2026, 23:13 UTC

Ergebnisse

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29. Apr. 2026, 23:12 UTC

Ergebnisse

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29. Apr. 2026, 23:11 UTC

Ergebnisse

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29. Apr. 2026, 23:04 UTC

Ergebnisse

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29. Apr. 2026, 23:04 UTC

Ergebnisse

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer-Vergleich

Kursveränderung

Smith & Nephew PLC ADR Prognose

Kursziel

By TipRanks

2.96% Vorteil

12-Monats-Prognose

Durchschnitt 32 USD  2.96%

Hoch 32 USD

Tief 32 USD

Basierend auf 1 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

1 ratings

0

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

26.64 / 28.37Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat